These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 29950962)

  • 1. The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer.
    Steven A; Seliger B
    Breast Care (Basel); 2018 Mar; 13(1):16-21. PubMed ID: 29950962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.
    Law AM; Lim E; Ormandy CJ; Gallego-Ortega D
    Endocr Relat Cancer; 2017 Apr; 24(4):R123-R144. PubMed ID: 28193698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells.
    Singh S; Chakrabarti R
    J Clin Med; 2019 May; 8(5):. PubMed ID: 31075939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape.
    Perea F; Sánchez-Palencia A; Gómez-Morales M; Bernal M; Concha Á; García MM; González-Ramírez AR; Kerick M; Martin J; Garrido F; Ruiz-Cabello F; Aptsiauri N
    Oncotarget; 2018 Jan; 9(3):4120-4133. PubMed ID: 29423109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study.
    Lopes MLDS; Gonzaga AKG; Mosconi C; Palomino GM; Mendonça EF; Batista AC; Silveira ÉJDD
    Arch Oral Biol; 2019 Feb; 98():99-107. PubMed ID: 30468994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment.
    Li JJ; Tsang JY; Tse GM
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. If we build it they will come: targeting the immune response to breast cancer.
    Gatti-Mays ME; Balko JM; Gameiro SR; Bear HD; Prabhakaran S; Fukui J; Disis ML; Nanda R; Gulley JL; Kalinsky K; Abdul Sater H; Sparano JA; Cescon D; Page DB; McArthur H; Adams S; Mittendorf EA
    NPJ Breast Cancer; 2019; 5():37. PubMed ID: 31700993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
    Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
    Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
    Seliger B
    HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation.
    Rodríguez JA
    Oncol Lett; 2017 Oct; 14(4):4415-4427. PubMed ID: 29085437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma.
    Ottenhof SR; Djajadiningrat RS; Thygesen HH; Jakobs PJ; Jóźwiak K; Heeren AM; de Jong J; Sanders J; Horenblas S; Jordanova ES
    Front Immunol; 2018; 9():1253. PubMed ID: 29942303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions.
    Azadi S; Aboulkheyr Es H; Razavi Bazaz S; Thiery JP; Asadnia M; Ebrahimi Warkiani M
    Biochim Biophys Acta Mol Cell Res; 2019 Dec; 1866(12):118526. PubMed ID: 31398408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
    Kim JM; Chen DS
    Ann Oncol; 2016 Aug; 27(8):1492-504. PubMed ID: 27207108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?
    Deligne C; Midwood KS
    Front Oncol; 2021; 11():620773. PubMed ID: 33718177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
    Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
    Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.